HPV vaccines for treatment and prevention of recurrent respiratory papillomatosis

Recurrent respiratory papillomatosis (RRP) is a disease of viral etiology and is caused by the human papillomavirus (HPV). Although it is a benign disease process, there are very serious sequelae because of its involvement in the tracheobronchial tree. While there are multiple treatment modalities, ranging from surgery to antivirals and immunomodulating chemotherapeutics, recent advances have focused on the prevention of HPV transmission with vaccines. Over the last 10 years, HPV vaccinations have been increasingly employed and the CDC currently recommends the use of the new nine-valent vaccine (Gardasil-9). The increasing use of a nine-valent vaccine offers hope for preventing the neonatal transmission of the HPV virus and significantly reducing the incidence and morbidity of RRP and other HPV-related diseases.